65,437 trials
Advanced Bladder Urothelial Carcinoma · Advanced Ureter Urothelial Carcinoma · Metastatic Bladder Urothelial Carcinoma
Primary: Objective Response Rate (ORR) — 3; 4; 0; 2 Participants — p=0.428
Hepatitis B, Chronic
Primary: Percentage of Participants With a Reduction of at Least 2 log10 International Unit/Millilitres (IU/mL) in Hepatitis B Surface Antigen (HBsAg) Levels From Baseline to…
Back Pain · Postural Low Back Pain · Lower Back Pain
Primary: Score on Numeric Pain Rating Scale (NPRS) — 2.54; 2.44; 1.75; 1.49 score on a scale
Myelodysplastic Syndromes · Chronic Myelomonocytic Leukemia · Acute Myeloid Leukemia
Primary: Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV Decitabine — 864.34; 855.96; 910.1; 900.5 hours*nanograms per…
Caregiver · Hematologic Malignancy
Primary: Feasibility of the PATH Intervention — 15; 13; 15 participants
Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) at 3 Months — 12.3 score on a scale
Pain
Primary: Pain Change — -3.8; -4.0 units on a scale — p=<0.05
Photoreceptor Sensitivity Thresholds
Primary: Time to Rod-cone Break (RCB) — 11.34; 9.98 Minutes
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Advanced Solid Tumor Diseases
Primary: Participant Meaning Making Scores Using the Life Attitude Profile-Revised (LAP-R) — 37.07; 38.28; 36.80; 42.22 scores on a scale
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale for DSM-5 to Assess Changes in PTSD Symptoms. — 35.3; 11.33 score on scale
Metastatic Endometrial Cancer
Primary: Progression Free Survival (PFS) — 28.1; 8.7 months
PTSD
Primary: Change in Clinician-Administered PTSD Scale for DSM-5 — 38.39; 35.67; 27.15; 29.31 score on a scale — p=0.4154
Unemployment · Mental Illness · Substance Use Disorder
Primary: Competitive Employment Within Six Months of Random Assignment. — 15; 25 Participants — p==.016
Knee Osteoarthritis · Obesity · Depression
Primary: Treatment Adherence — 24; 18 Participants